Ken Griffin Novartis Ag Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	SELL	$95.27 - $108.47 $15.5 Million - $17.7 Million	-163,100 Reduced 58.88%	113,900 $11 Million
Q4 2023 Feb 14, 2024	BUY	$92.27 - $101.54 $9.84 Million - $10.8 Million	106,600 Added 62.56%	277,000 $28 Million
Q3 2023 Nov 14, 2023	SELL	$94.73 - $105.13 $26.7 Million - $29.7 Million	-282,100 Reduced 62.34%	170,400 $17.4 Million
Q2 2023 Aug 14, 2023	BUY	$92.52 - $104.91 $1.09 Million - $1.24 Million	11,800 Added 2.68%	452,500 $45.7 Million
Q1 2023 May 15, 2023	SELL	$80.03 - $92.81 $35.3 Million - $40.9 Million	-440,500 Reduced 49.99%	440,700 $40.5 Million

Q4 2022 Feb 14, 2023	BUY	$75.55 - $92.52 $10.9 Million - $13.4 Million	144,600 Added 19.63%	881,200 $79.9 Million
Q3 2022 Nov 14, 2022	SELL	$74.61 - $87.26 $2.53 Million - $2.96 Million	-33,900 Reduced 4.4%	736,600 $56 Million

1,343

140M

1.15M

866K

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $229B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.